NAMS
NewAmsterdam Pharma Company N.V.
22.10$
-0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1,201.0% | -4,118.8% | -3,897.4% | -2,368.5% | -42.9% | -293.5% | -1,224.6% | -196.8% | -9,416.4% | -127,734.4% | -1,006.7% | -1,059.6% | -2,014.6% | |
| 0.2% | 1.6% | 1.1% | 0.8% | 0.1% | 0.4% | 1.7% | 0.2% | 18.4% | 184.4% | 2.0% | 1.6% | 3.4% | |
| 188.9% | 747.9% | 565.2% | 363.8% | 27.5% | 73.7% | 510.8% | 79.3% | 4,313.2% | 43,821.9% | 592.2% | 496.6% | 918.6% | |
| 89.2% | 1,163.0% | -723.6% | -640.0% | 0.1% | -62.5% | 347.6% | -124.5% | -2,974.4% | 14,265.6% | 134.7% | 39.0% | -3.5% | |
| 0.3% | 0.4% | 27.5% | 9.2% | 0.3% | 0.0% | 0.5% | 0.5% | 12.1% | 312.5% | 1.3% | 2.2% | 3.7% | |
| -88.4% | -0.4% | -27.5% | -9.2% | -0.3% | -486.8% | 95.9% | -831.2% | 720.1% | -66,065.6% | -378.6% | -128.7% | -490.2% | |
| 6.8% | 2.5% | 14,145.6% | 204.4% | 0.2% | 3,575.1% | 218.9% | 17.9% | 1,693.1% | 42,762.5% | 364.0% | 298.3% | 585.3% | |
| -1,110.2% | -3,469.1% | 10,042.6% | -2,213.2% | -27.4% | 2,732.6% | -783.2% | -964.0% | -6,939.4% | -151,225.0% | -1,065.1% | -903.4% | -1,942.9% | |
| -1,201.3% | -4,119.2% | -3,924.8% | -2,377.7% | -43.2% | -293.5% | -1,225.1% | -197.2% | -9,428.4% | -128,046.9% | -1,008.0% | -1,061.7% | -2,018.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.